Literature DB >> 837634

Clinical effects and pharmacokinetics of racemic methadone and its optical isomers.

G D Olsen, H A Wendel, J D Livermore, R M Leger, R K Lynn, N Gerber.   

Abstract

The respiratory and pupillary effects of oral l-, d-, and d,l-methadone were studied in healthy male volunteers 21 to 35 yr of age. The mean half-life of drug in blood was 22 hr for racemic methadone, 24 hr for l-methadone, and 25 hr for d-methadone. The effects of d-methadone were not significantly different from the placebo response at a 7.5 mg dose, whereas a 50 and 100 mg dose slightly depressed respiration in one subject each. Both 7.5 mg of l-methadone and 15 mg of d,l-methadone induced intense and sustained respiratory depression and miosis. The changes induced by l-methadone were of longer duration than those of d,l-methadone, lasting more than 72 hr in some subjects. Whole blood drug concentration correlated well with respiratory depression and miosis for l- and d,,l-methadone. The potency ratio of l-methadone to d,l-methdone, calculated from blood drug concentration data, was found to be 3.0 for respiratory depression and 2.7 for miosis. The antiduretic effect of 15 mg of d,l-methadone was investigated in three subjects and was found to persist for as long as measurements were taken, namely 11 and 12 hr in two subjects. d,l-Methadone administered frequently for pain may have cumulative effects on respiratory control and ability to excrete a water load.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837634     DOI: 10.1002/cpt1977212147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

4.  Fatal methadone overdose.

Authors:  T J Hendra; S P Gerrish; A R Forrest
Journal:  BMJ       Date:  1996-08-24

Review 5.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.

Authors:  Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 7.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

8.  The acute disposition of (R)- and (s)-methadone in brain and lung of sheep.

Authors:  David J R Foster; Richard N Upton; Andrew A Somogyi; Cliff Grant; Allison Martinez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

9.  Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

Authors:  E Anggård; M I Nilsson; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

10.  Patient-controlled dose regimen of methadone for chronic cancer pain.

Authors:  J Säwe; J Hansen; C Ginman; P Hartvig; P A Jakobsson; M I Nilsson; A Rane; E Anggård
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.